Apr 27, 2009 - Alkermes, Inc. today announced that Janssen Pharmaceutica K.K. received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to market RISPERDAL CONSTA [(risperidone) long-acting injection] for the treatment of schizophrenia.
The details can be read here.
No comments:
Post a Comment